Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes.
about
The Myocardial Ischemia Reduction with Acute Cholesterol Lowering trial: MIRACuLous or not, it's time to change current practice.Clinical and economic studies of eptifibatide in coronary stentingGlycoprotein receptor inhibitors in the management of acute coronary syndromesEstimating incremental cost-effectiveness ratios and their confidence intervals with differentially censored data.On estimating medical cost and incremental cost-effectiveness ratios with censored data.Cost-effectiveness analysis using data from multinational trials: the use of bivariate hierarchical modelingEstimating utility data from clinical indicators for patients with stable angina.Use of glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST-elevation myocardial infarction.The analysis of multinational cost-effectiveness data for reimbursement decisions: a critical appraisal of recent methodological developments.Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines.Cost effectiveness of treatments for non-ST-segment elevation acute coronary syndrome.Choice of GPIIb/IIIa antagonist in percutaneous coronary intervention: how should economic criteria be factored in?Cost Effectiveness of Antiplatelet and Antithrombotic Therapy in the Setting of Acute Coronary Syndrome: Current Perspective and Literature Review.Spotlight on eptifibatide in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.The average lifespan of patients discharged from hospital with heart failurePresent and evolving role of eptifibatide in the treatment of acute coronary syndromes.Antiplatelet therapy in patients with unstable angina and non-ST-segment-elevation myocardial infarction: findings from the CRUSADE national quality improvement initiative.Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulatorQuality of life after late invasive therapy for occluded arteries.Cost-effectiveness Analysis Appraisal and Application: An Emergency Medicine Perspective.Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.Cost effectiveness of fondaparinux in non-ST-elevation acute coronary syndrome.A comparison of total hospital costs for percutaneous coronary intervention patients receiving abciximab versus tirofiban.Cost efficacy of platelet glycoprotein IIb/IIIa antagonists in clinical trials and clinical practice.Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial.Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.Pharmacotherapy of acute coronary syndromes: medical economics with an emphasis on clopidogrel.Empirical estimation of life expectancy from large clinical trials: use of left-truncated, right-censored survival analysis methodology.Unit costs in international economic evaluations: resource costing of the Schizophrenia Outpatient Health Outcomes Study
P2860
Q24794251-31C847D8-8BF0-40F1-8D0D-46C70BF21DF9Q26830199-C3A344B0-CFF6-4AD5-8282-250F1002EB26Q28193156-7D0E7D92-B07A-4D19-8B91-CCDEC4F06D73Q30441326-6E0B8C4A-4948-4283-A032-8F13B7661E75Q30667819-8CDC2F0E-ECF5-4AE4-AF1A-ABAC1DDEB59DQ31119280-1E6038D1-F098-495A-BF6E-F0E66A426B88Q33224199-8A2E3910-44A9-4C2B-A9B8-C803472EC4A3Q33369310-292BBBE0-2EE8-494A-B4FA-0F423C1BDFF4Q33748108-44D9B8FC-2994-46DF-A031-C57432D89290Q34445660-E7392195-4A27-41FF-A34E-8C476B1D8877Q35216895-5122E773-5B2E-45B5-A7DF-26F9CF9548F0Q36184702-BCBCFB25-36E5-4A97-B156-A44ABC1CF18DQ36322605-00B3887D-D08F-4703-8F47-899F4B2566E0Q36435646-F46A5755-A46E-4AA7-99F8-F3006A45E22CQ36447299-685F9C96-CD27-4913-9791-CC5DA931FCBBQ36815950-AF5DFFA9-4515-4349-B778-71A163D91AFFQ36892804-167CCDD2-E87D-47D1-87C8-741C67538503Q36949147-3CA6D6CD-B9C8-4D55-8C00-A229371F5D7EQ37298262-6910D64D-6DFF-4320-AD53-ABD2046824C2Q38906525-55077FC4-5897-4823-B936-78624B4A9380Q43005398-58825A2C-8C2D-476C-ACD5-D6516BDE97BFQ43296471-28CD3324-D0A8-4783-BFEC-54F6C1B0C2B4Q43759391-36BAFB77-6EDF-49C6-B6EB-C44C9D779FDFQ44027345-F4C1143B-17E1-4742-9F5F-2C9015021E3EQ44839970-FF821B19-54AC-473D-881E-A25094A9D9C8Q46582354-220F9BAD-E58C-422E-8256-0D79D1FA83D8Q46722941-B443A8CA-0064-4D5A-B694-00916C15440CQ50126504-95C11BC1-1A00-4732-9D09-CBD879C5A81FQ57709587-57418563-BE36-4989-A433-DD86849F6CD3
P2860
Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Cost-effectiveness of platelet ...... tion acute coronary syndromes.
@ast
Cost-effectiveness of platelet ...... tion acute coronary syndromes.
@en
type
label
Cost-effectiveness of platelet ...... tion acute coronary syndromes.
@ast
Cost-effectiveness of platelet ...... tion acute coronary syndromes.
@en
prefLabel
Cost-effectiveness of platelet ...... tion acute coronary syndromes.
@ast
Cost-effectiveness of platelet ...... tion acute coronary syndromes.
@en
P2093
P50
P356
P1433
P1476
Cost-effectiveness of platelet ...... tion acute coronary syndromes.
@en
P2093
A A Tsiatis
C L Nelson
K W Mahaffey
L Davidson-Ray
R A Harrington
P304
P356
10.1161/01.CIR.101.4.366
P407
P577
2000-02-01T00:00:00Z